INTERVIEW · HEALTH · Entrada Therapeutics · Milken Global Conference 2025 · 10:19 · Released September 30, 2026
"We still don’t fundamentally know how therapeutics get into cells. Solving that is now in human trials for Duchenne." - Milken Global 2025
Entrada Therapeutics’ CEO on a platform that carries therapeutics into cells and directs them where they need to go: functional cures for Duchenne muscular dystrophy now in clinical trials in Europe, a myotonic dystrophy partnership with Vertex, how rare-disease trials find patients through advocacy groups, and why newborn screening is the key to treating early.
HealthcareScience
Up next
More like this5:02
What's the Future of the Brain?
Healthcare
4:37
What's the Future of Longevity?
Healthcare
11:55
In Many Health Centres There Is Nobody to Ask | Samsung Healthcare | Healthcare AI
RSNA 2025
11:19
Technology, Cloud and the Future, GCC Conclave 2019
Ian Khan · GCC Conclave 2019
3:43
Reducing the Friction Between Government and People | Ian Khan at WGS 2024
Government Experience
9:26
Applying 'Never Events' Thinking to Clinical AI | Dr Erin Palm, Infinitus
ViVE 2026
11:08
Personalisation Does Not Matter Equally to Every Brand - Possible 2025
POSSIBLE Miami 2025
9:04
It Is Impossible to Debank Someone | Dom Kwok, EasyA
Consensus 2025 Toronto
11:43
A Billion Women Still Lack a Bank Account | Mary Ellen Iskenderian, Women's World Banking
Mary Ellen Iskenderian, Women's World Banking · Money20/20 USA 2026
10:45
AI Agents That Join the Fraud Team | Roy Zur, Charm Security
Roy Zur, Charm Security · Money20/20 USA 2026